Right ventricular outflow tract velocity time integral-to-pulmonary artery systolic pressure ratio: a non-invasive metric of pulmonary arterial compliance differs across the spectrum of pulmonary hypertension.

Cpc-PH non-invasive pulmonary arterial compliance pulmonary hypertension

Journal

Pulmonary circulation
ISSN: 2045-8932
Titre abrégé: Pulm Circ
Pays: United States
ID NLM: 101557243

Informations de publication

Date de publication:
Historique:
pubmed: 19 3 2019
medline: 19 3 2019
entrez: 19 3 2019
Statut: ppublish

Résumé

Pulmonary arterial compliance (PAC), invasively assessed by the ratio of stroke volume to pulmonary arterial (PA) pulse pressure, is a sensitive marker of right ventricular (RV)-PA coupling that differs across the spectrum of pulmonary hypertension (PH) and is predictive of outcomes. We assessed whether the echocardiographically derived ratio of RV outflow tract velocity time integral to PA systolic pressure (RVOT-VTI/PASP) (a) correlates with invasive PAC, (b) discriminates heart failure with preserved ejection-associated PH (HFpEF-PH) from pulmonary arterial hypertension (PAH), and (c) is associated with functional capacity. We performed a retrospective cohort study of patients with PAH (n = 70) and HFpEF-PH (n = 86), which was further dichotomized by diastolic pressure gradient (DPG) into isolated post-capillary PH (DPG < 7 mmHg; Ipc-PH, n = 54), and combined post- and pre-capillary PH (DPG ≥ 7 mm Hg; Cpc-PH, n = 32). Of the 156 patients, 146 had measurable RVOT-VTI or PASP and were included in further analysis. RVOT-VTI/PASP correlated with invasive PAC overall (ρ = 0.61, P < 0.001) and for the PAH (ρ = 0.38, P = 0.002) and HFpEF-PH (ρ = 0.63, P < 0.001) groups individually. RVOT-VTI/PASP differed significantly across the PH spectrum (PAH: 0.13 [0.010-0.25] vs. Cpc-PH: 0.20 [0.12-0.25] vs. Ipc-PH: 0.35 [0.22-0.44]; P < 0.001), distinguished HFpEF-PH from PAH (AUC = 0.72, 95% CI = 0.63-0.81) and Cpc-PH from Ipc-PH (AUC = 0.78, 95% CI = 0.68-0.88), and remained independently predictive of 6-min walk distance after multivariate analysis (standardized β-coefficient = 27.7, 95% CI = 9.2-46.3; P = 0.004). Echocardiographic RVOT-VTI/PASP is a novel non-invasive metric of PAC that differs across the spectrum of PH. It distinguishes the degree of pre-capillary disease within HFpEF-PH and is predictive of functional capacity.

Identifiants

pubmed: 30880577
doi: 10.1177/2045894019841978
pmc: PMC6540515
doi:

Types de publication

Journal Article

Langues

eng

Pagination

2045894019841978

Subventions

Organisme : NHLBI NIH HHS
ID : K24 HL103844
Pays : United States

Références

J Am Soc Echocardiogr. 2006 Aug;19(8):1045-50
pubmed: 16880101
J Am Soc Echocardiogr. 2010 Jul;23(7):685-713; quiz 786-8
pubmed: 20620859
Am J Respir Crit Care Med. 2011 Jan 15;183(2):268-76
pubmed: 20709819
Circulation. 2012 Jan 17;125(2):289-97
pubmed: 22131357
Circulation. 2012 Jul 17;126(3):349-56
pubmed: 22696079
Circ Cardiovasc Imaging. 2012 Nov;5(6):765-75
pubmed: 22914595
Chest. 2013 Mar;143(3):758-766
pubmed: 23580984
Am J Cardiol. 2013 Sep 15;112(6):873-82
pubmed: 23735649
J Heart Lung Transplant. 2013 Aug;32(8):777-83
pubmed: 23773508
Curr Opin Pulm Med. 2013 Sep;19(5):437-45
pubmed: 23884296
J Am Soc Echocardiogr. 2013 Nov;26(11):1322-9
pubmed: 23928091
Am J Physiol Heart Circ Physiol. 2013 Nov 1;305(9):H1373-81
pubmed: 23997100
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D100-8
pubmed: 24355634
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D109-16
pubmed: 24355635
Circulation. 2014 Dec 23;130(25):2310-20
pubmed: 25391518
Chest. 2015 Jul;148(1):226-234
pubmed: 25633590
JACC Heart Fail. 2015 Jun;3(6):467-474
pubmed: 26046840
Am J Respir Crit Care Med. 2015 Nov 15;192(10):1234-46
pubmed: 26181215
Eur Heart J. 2016 Jan 1;37(1):67-119
pubmed: 26320113
Ann Am Thorac Soc. 2016 Feb;13(2):276-84
pubmed: 26848601
J Am Soc Echocardiogr. 2016 Apr;29(4):277-314
pubmed: 27037982
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
J Heart Lung Transplant. 2017 Jan;36(1):97-105
pubmed: 27469015
Pulm Circ. 2016 Sep;6(3):313-21
pubmed: 27683608
J Cardiovasc Med (Hagerstown). 2017 Apr;18(4):237-243
pubmed: 27841823
J Am Coll Cardiol. 2016 Dec 13;68(23):2525-2536
pubmed: 27931609
JACC Cardiovasc Imaging. 2017 Oct;10(10 Pt B):1211-1221
pubmed: 28412423
JACC Cardiovasc Imaging. 2017 Oct;10(10 Pt B):1268-1277
pubmed: 28412426
Eur Heart J Cardiovasc Imaging. 2018 Apr 1;19(4):425-432
pubmed: 28531295
Eur J Heart Fail. 2017 Dec;19(12):1664-1671
pubmed: 28597497
Pulm Circ. 2017 Apr-Jun;7(2):399-408
pubmed: 28597758
Pulm Circ. 2017 Apr-Jun;7(2):361-371
pubmed: 28597759
Circ Heart Fail. 2017 Sep;10(9):null
pubmed: 28912263
Eur Respir J. 2019 Jan 24;53(1):null
pubmed: 30545974

Auteurs

Priyanka T Bhattacharya (PT)

1 Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
2 Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

Gregory S Troutman (GS)

3 Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA.

Frances Mao (F)

2 Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

Arieh L Fox (AL)

4 Department of Medicine, Division of Cardiovascular Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

Monique S Tanna (MS)

4 Department of Medicine, Division of Cardiovascular Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

Payman Zamani (P)

4 Department of Medicine, Division of Cardiovascular Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

E Wilson Grandin (EW)

5 Division of Cardiology, Richard A. and Susan F. Smith Center for Cardiovascular Outcomes Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Jonathan N Menachem (JN)

6 Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University, Nashville, TN, USA.

Edo Y Birati (EY)

4 Department of Medicine, Division of Cardiovascular Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

Julio A Chirinos (JA)

4 Department of Medicine, Division of Cardiovascular Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

Sula Mazimba (S)

7 University of Virginia Health System, Charlottesville, VA, USA.

Kerri Akaya Smith (KA)

8 Department of Medicine, Pulmonary Hypertension Program, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
9 Department of Medicine, Division of Pulmonary, Allergy and Critical Care, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

Steven M Kawut (SM)

1 Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
8 Department of Medicine, Pulmonary Hypertension Program, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
9 Department of Medicine, Division of Pulmonary, Allergy and Critical Care, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

Paul R Forfia (PR)

10 Pulmonary Hypertension, Right Heart Failure and Pulmonary Thromboendarterectomy Program, Temple University Hospital, Philadelphia, PA, USA.

Anjali Vaidya (A)

10 Pulmonary Hypertension, Right Heart Failure and Pulmonary Thromboendarterectomy Program, Temple University Hospital, Philadelphia, PA, USA.

Jeremy A Mazurek (JA)

4 Department of Medicine, Division of Cardiovascular Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
8 Department of Medicine, Pulmonary Hypertension Program, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

Classifications MeSH